Choosing the Right Drug-Eluting Stent for the SFA: Insights from the REALDES Study

Dr Marianne Brodmann discusses 3-year results from the REALDES study, a real-world comparison of the Zilver PTX and Eluvia drug-eluting stents for femoropopliteal disease conducted in Japan. Dr Brodmann shares her approach to high-risk patients and why Zilver PTX is her preferred choice for patients at elevated risk of restenosis or reocclusion.

• Both stents performed similarly in primary patency and CD-TLR despite the Zilver PTX arm having significantly longer lesions. 
• Patients treated with Zilver PTX had significantly lower rates of in-stent occlusions (Tosaka class III) than patients treated with Eluvia.